ArticleScientific reports2025
Integrating brain proteomes and genetics to identify novel risk genes in chronic widespread musculoskeletal pain.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gmppb-mutant mice exhibit dystroglycanopathy symptoms that are rescued with GSK3β inhibition or AAV-mediated GMPPB gene replacement.Nature communications · 2026Article
- Modeling Pain Without Injury: Inherited Rodent Models as Mechanistic Windows into Chronic Pain.Function (Oxford, England) · 2025Review
- Identification and validation of novel risk genes for intervertebral disc disorder by integrating large-scale multi-omics analyses and experimental studies.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic widespread musculoskeletal pain (CWP), a core symptom of fibromyalgia, is a complex condition with an unclear pathogenesis. Despite findings from genome-wide association studies (GWAS), translating genetic risk variants into therapeutic targets remains challenging due to limited understanding of their functional roles in CWP. In this study, we developed an integrative analytical pipeline to efficiently link genetic associations with novel risk genes for CWP. By combining high-throughput data from multiple sources, we integrated proteome-wide association studies (PWAS), transcriptome-wide association studies (TWAS), summary-based Mendelian randomization (SMR), and Bayesian co-localization analyses. This approach allowed us to prioritize genes that may increase the risk of CWP by altering protein abundance and gene expression in the brain. We further examined these genes using various advanced methodologies to validate their significance. We identified eight genes expressed in the brain, whose protein levels were associated with CWP. Four of these genes were confirmed through a subsequent PWAS, while three showed associations with cis-regulated mRNA expression. Only four genes, GMPPB, COMT, NME1, and GPX1, passed SMR and Bayesian colocalization analyses. These genes were expressed in pain-related brain regions and showed selective expression in oligodendrocytes, microglia, dopaminergic neurons, and interneurons. Additionally, COMT and NME1 were identified as potential druggable targets using the DGIdb and DrugBank databases. Our findings suggest that GMPPB, COMT, NME1, and GPX1 are potential risk genes for CWP, offering new insights into the molecular mechanisms underlying the condition. These genes represent promising targets for future research and therapeutic intervention development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.